What is the recommended treatment for H pylori (Helicobacter pylori) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

H. pylori Treatment

First-Line Treatment Recommendation

Bismuth quadruple therapy for 14 days is the preferred first-line treatment for H. pylori infection, consisting of a high-dose PPI twice daily, bismuth subsalicylate, tetracycline, and metronidazole. 1, 2

This recommendation is based on:

  • High efficacy (80-90% eradication rates) even against clarithromycin and metronidazole-resistant strains due to bismuth's synergistic effect 1, 2
  • Clarithromycin resistance now exceeds 15% in most regions, making traditional triple therapy unacceptably ineffective 2, 3
  • No bacterial resistance to bismuth has been described, making this regimen reliable across all resistance patterns 1, 2

Specific Dosing Regimen

  • PPI (esomeprazole or rabeprazole preferred): 40 mg twice daily, taken 30 minutes before meals on an empty stomach 1, 2
  • Bismuth subsalicylate: 262 mg (2 tablets) four times daily 1
  • Metronidazole: 500 mg three to four times daily (total 1.5-2 g daily) 1, 2
  • Tetracycline: 500 mg four times daily 1, 2
  • Duration: 14 days (mandatory—improves eradication by ~5% compared to shorter regimens) 1, 2

Alternative First-Line Option (When Bismuth Unavailable)

Concomitant non-bismuth quadruple therapy for 14 days is the recommended alternative when bismuth is not available 2, 3:

  • PPI: Twice daily (high-dose preferred)
  • Amoxicillin: 1000 mg twice daily 2
  • Clarithromycin: 500 mg twice daily 2
  • Metronidazole: 500 mg twice daily 2

Critical caveat: This regimen should only be used when local clarithromycin resistance is <15%, which is now rare in most regions 2, 3

Second-Line Treatment After First-Line Failure

If Bismuth Quadruple Therapy Was NOT Used First-Line:

Use bismuth quadruple therapy for 14 days (as described above) 1, 2

If Bismuth Quadruple Therapy Failed:

Levofloxacin-based triple therapy for 14 days (if no prior fluoroquinolone exposure) 1, 2:

  • PPI: Twice daily (high-dose)
  • Amoxicillin: 1000 mg twice daily 1, 2
  • Levofloxacin: 500 mg once daily OR 250 mg twice daily 1, 2

Important warning: Levofloxacin resistance is rising (11-30% primary, 19-30% secondary resistance), so avoid if patient has had any prior fluoroquinolone exposure for any indication 1, 2

Third-Line and Rescue Therapies

After Two Failed Attempts:

Antimicrobial susceptibility testing should guide further treatment whenever possible 1, 2

When Susceptibility Testing Unavailable:

Option 1: Rifabutin-based triple therapy for 14 days 1, 2:

  • Rifabutin: 150 mg twice daily
  • Amoxicillin: 1000 mg twice daily
  • PPI: Twice daily (high-dose)
  • Advantage: Rifabutin resistance is extremely rare 1

Option 2: High-dose dual amoxicillin-PPI therapy for 14 days 1:

  • Amoxicillin: 2-3 grams daily in 3-4 divided doses
  • PPI: Double standard dose, twice daily

Critical Optimization Factors

PPI Dosing (Applies to ALL Regimens):

  • High-dose PPI twice daily is mandatory—increases eradication efficacy by 6-10% compared to standard dosing 1, 2
  • Esomeprazole or rabeprazole 40 mg twice daily preferred—may increase cure rates by an additional 8-12% compared to other PPIs 1, 2
  • Timing: Take 30 minutes before meals on an empty stomach, without concomitant antacids 1

Treatment Duration:

  • 14 days is mandatory for all regimens—improves eradication by ~5% compared to 7-10 day regimens 1, 2

Antibiotic Selection Principles:

  • Never repeat antibiotics previously used, especially clarithromycin and levofloxacin—resistance develops rapidly after exposure 1, 2
  • Amoxicillin, tetracycline, and bismuth can be re-used because resistance remains rare (<5%) 1, 2
  • Metronidazole can be re-used with bismuth because bismuth's synergistic effect overcomes in vitro resistance 1, 2

Verification of Eradication

Confirm eradication with urea breath test or monoclonal stool antigen test: 1, 2

  • At least 4 weeks after completion of therapy
  • At least 2 weeks after PPI discontinuation
  • Never use serology—antibodies persist long after successful treatment 1, 2

Special Populations

Penicillin Allergy:

Bismuth quadruple therapy is the first choice (contains tetracycline, not amoxicillin) 1, 2

Consider penicillin allergy testing to delist the allergy and enable amoxicillin use, as amoxicillin resistance remains rare 1

H. pylori with Amoxicillin for Dual Therapy (FDA-Approved):

For dual therapy: 1 gram amoxicillin three times daily (every 8 hours) with 30 mg lansoprazole three times daily for 14 days 4

For triple therapy: 1 gram amoxicillin twice daily (every 12 hours) with 500 mg clarithromycin and 30 mg lansoprazole, all twice daily for 14 days 4

Common Pitfalls and How to Avoid Them

Pitfall #1: Inadequate PPI Dosing

Solution: Always use high-dose PPI twice daily (not once daily, not standard dose)—this single factor increases efficacy by 6-10% 1, 2

Pitfall #2: Using Clarithromycin-Based Triple Therapy in High-Resistance Areas

Solution: Abandon standard triple therapy when regional clarithromycin resistance exceeds 15%—this threshold has been surpassed in most of North America and Europe 2, 3

Pitfall #3: Repeating Failed Antibiotics

Solution: Avoid clarithromycin and levofloxacin if previously used for ANY indication (not just H. pylori)—cross-resistance is universal within antibiotic classes 1, 2

Pitfall #4: Inadequate Treatment Duration

Solution: Always prescribe 14 days—shorter regimens have unacceptably lower cure rates 1, 2

Pitfall #5: Poor Patient Compliance

Solution: Address compliance issues proactively—more than 10% of patients are poor compliers, leading to much lower eradication rates 1

Consider adjunctive probiotics to reduce antibiotic-associated diarrhea (occurs in 21-41% of patients) and improve compliance, though probiotics do not increase eradication rates 2, 3

Patient Factors Affecting Success

  • Smoking: Increases risk of eradication failure (OR 1.95) 1
  • High BMI/obesity: Increases failure risk due to lower drug concentrations at gastric mucosal level 1
  • Prior antibiotic exposure: Any prior macrolide or fluoroquinolone use (for any indication) increases resistance risk 1, 2

References

Guideline

Treatment for Persistent Helicobacter pylori Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Helicobacter pylori Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Helicobacter Pylori Infection Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.